你可能會喜歡
$CYTK going to see $70 pre PDUFA. Label is especially important here. Intend to open a call spread closer to the event to max out premium. Will always been a OPP to add again in the future if it gets called away. Will wait until just before event(few weeks) as there is a buyout…
28 hours until a face ripping re-rate of $SLNO valuation
Biotech investing is not for everyone If you don’t know the sector best is to stay away So many variables to work against So many unknowns FDA, clinical data, safety, competition and cash crunch some variables that can affect the outcome of your investment But there’s…
The uncertainty in biotech is supposed to come from clinical data risk -- NOT regulatory whiplash at the FDA. This will scare away much of the generalist capital that was finally looking at biotech again ( $QURE top holders include non-biotech specialists like Jefferies,…
Is there any precedent for the FDA reversing BLA regulatory guidance/commitments that they agreed to literally just four months ago? This FDA reversal feels like the type of thing that would make it impossible to plan or invest in biopharma. Uniqure $QURE FDA Alignment in June…
$OTLK - with BLA re-submission PDUFA will likely be circa May next year(Class 2/ pending FDA). Will likely do a little raise but bounced 2X + the last time. Another interesting trade with good R:R into next year!
$QURE $30. Huge bounce from drop to $11s. These crash and bounce trades present big opportunities in Biotech.
$QURE - pretty massive dip buy opportunity for the long term. Went to $11.24👀. Plenty of risk but R:R here compelling.
$QURE - pretty massive dip buy opportunity for the long term. Went to $11.24👀. Plenty of risk but R:R here compelling.
$LQDA - PROFITABILITY - nicely done Achieved profitability in the first full quarter of YUTREPIA sales
$LQDA Q3 YUTREPIA net product sales of $51.7M - Achieved profitability in the first full quarter of YUTREPIA sales - More than 2,000 unique patient prescriptions and 1,500 patient starts to date. - Cash and cash equivalents $157.5M $UTHR
Largest beat on early launch revenue I can remember for some time - simple WOW!Nearly 30% of the float short. New highs incoming. $LQDA
Massive Beat $LQDA - this one going to rock.
$LQDA Q3 YUTREPIA net product sales of $51.7M - Achieved profitability in the first full quarter of YUTREPIA sales - More than 2,000 unique patient prescriptions and 1,500 patient starts to date. - Cash and cash equivalents $157.5M $UTHR
$CRBU update on its off-the-shelf CAR-T programs at 7 am ET.
Did I read that Piper report correctly - $80👀. To be clear I’m fine with $8😌. $UNCY
Now that $NTLA is officially on clinical hold by the FDA, this is one of the most ridiculously overpriced valuations I've seen. The stock continuing to trade at $12.50 is insane to me - that's a >$800M enterprise value. It was as low as $5.90 after the first Grade 4 liver event…
Ok, so time to get serious on $NTLA. It is going to single digits. Total operating expenses in 1H25 were >$261M. That means that at the moment, they would have ~$500M cash. 107.3M shares outstanding means ~$4.66/share is cash value. BOTH of their lead programs have now had…
$PHAT 👀 - looks strong. Going to retest highs.
$PHAT Beat on Revenue Beat on Profit No more financing Profitability in 2026 Like this one into next year!
M&A drama, with a dose of "America First" politics! So much fun... Novo Nordisk $NVO makes offer for obesity-focused Metsera $MTSR, aiming to outbid Pfizer $PFE statnews.com/2025/10/30/nov… via @DrewQJoseph
$PHAT Beat on Revenue Beat on Profit No more financing Profitability in 2026 Like this one into next year!
$PFE is aware of the reckless and unprecedented proposal by $NVO to acquire $MTSR businesswire.com/news/home/2025…
$UNCY - Unicycive Therapeutics 🔹Provides Update from FDA Type A Meeting 🔹Planned NDA resubmission by year-end 2025 🔹Potential PDUFA date in H1 2026 🔹No clinical or safety concerns identified in FDA review 🔹$42 million cash as of September 30, 2025 supports runway into 2027…
United States 趨勢
- 1. Cowboys 64.3K posts
- 2. Cardinals 28.4K posts
- 3. #WWERaw 57.1K posts
- 4. Jerry 43.4K posts
- 5. Logan Paul 9,307 posts
- 6. Kyler 7,549 posts
- 7. Jacoby Brissett 4,701 posts
- 8. Koa Peat 5,790 posts
- 9. Pickens 6,377 posts
- 10. Javonte 3,888 posts
- 11. Cuomo 160K posts
- 12. Bland 11.5K posts
- 13. Dak Prescott 4,432 posts
- 14. Walter Nolen 1,624 posts
- 15. Calais Campbell N/A
- 16. Keba Keita N/A
- 17. Nick Smith 1,983 posts
- 18. Pacers 10.9K posts
- 19. #MondayNightFootball 1,304 posts
- 20. Steele 5,850 posts
Something went wrong.
Something went wrong.